Texas Children’s Cancer Center offers the following clinical trials for patients with Ewing sarcoma. For more detailed information such as current enrollment status and eligibility criteria for these trials, referring physicians may call 1-800-226-2379 (1-800-CANCER9). Families may contact us toll-free at 1-844-394-6471 (1-844-EWINGS1).
Also provided here is a Clinical Trials Search Tool, built in collaboration with
Institute for Clinical and Translational Research, Baylor College of Medicine,
that allows users to search for specific clinical trials anywhere in the United States.
|Study ID||Study Title||Principal Investigator|
|AEWS1031||A Phase III Randomized Trial of Adding Vincrstine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma||Dr. Lisa Wang|
|AEWS1221||Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metatastic Ewing||Dr. Nino Rainusso|
|SGT-53||A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children with Refractory or Recurrent Solid Tumors||Dr. Jodi Muscal|
|ADVL1312||A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors||Dr. Karen Rabin|
|ADVL1314||Phase 1 study of Eribulin Mesylate in Pediatric Patients with Recurrent or Refractory Solid Tumors (excluding CNS), including Lymphomas.||Dr. Jodi Muscal|
|ADVL1315||A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors||Dr. Jodi Muscal|
|ADVL1411||A Phase I/II Study of BMN 673 (IND#121510), an Oral Poly (ADP-Ribose) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies
|Dr. Jodi Muscal|
|ADVL1412||A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab||Dr. Karen Rabin|
|HEROS||Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma||Dr. Nabil Ahmed|